If a pharmacy has entered into a collaborative pharmacy practice agreement with one or more physicians pursuant to section 12-280-602 to administer injectable antagonist medication for medication-assisted treatment for substance use disorders, the pharmacy administering the drug shall receive an enhanced dispensing fee that aligns with the administration fee paid to a provider in a clinical setting.
Source: L. 2018: Entire section added, (HB 18-1007), ch. 225, p. 1433, § 7, effective January 1, 2019. L. 2019: Entire section amended, (HB 19-1172), ch. 136, p. 1710, § 188, effective October 1.